Marmara University School of Medicine, Department of Endocrinology and Metabolism, Istanbul, Turkey.
Marmara University School of Medicine, Department of Endocrinology and Metabolism, Istanbul, Turkey.
J Diabetes Complications. 2021 Dec;35(12):108073. doi: 10.1016/j.jdiacomp.2021.108073. Epub 2021 Oct 8.
Osteoprotegerin (OPG), a well-known protein that inhibits osteoclast formation and activity, might also be a potential marker for identifying patients with high cardiovascular risk. This study aimed to compare OPG levels, FMD, and CIMT measurements in subjects with vs. without diabetes and investigate the association of serum osteoprotegerin level with the early atherosclerotic markers, endothelial function, and carotid intima-media thickness (CIMT) in patients with type 2 diabetes mellitus (DM2).
Forty-nine patients with DM2 (F/M: 26/23, 49.3 ± 10.0 years) and 45 healthy volunteers (F/M: 26/19, 48.3 ± 7.5 years) were included in this cross-sectional study. Serum OPG levels were measured by solid-phase enzyme-linked immunosorbent assay (ELISA). Fasting plasma glucose (FPG) and HbA1c levels were measured. CIMT was measured by B-mode ultrasound, and endothelial function was evaluated via flow-mediated dilation (FMD) of the brachial artery with Doppler ultrasonography.
Serum OPG levels were significantly higher in patients with DM2 (617.0 ± 111.0 pg/mL) compared to controls (481.0 ± 96.0 pg/mL, p < 0.001). While CIMT in diabetic patients (0.65 + 0.13 mm) was higher than controls (0.54 ± 0.10 mm, p = 0.009), FMD measurement was lower in DM2 group (4.2% ± 3.1 mm vs. 7.6% ± 4.1 mm, p = 0.01). Univariate analysis showed that OPG was associated with the presence of diabetes (OR: 6.999, p = 0.001, R: 15.1%) and hypertension (OR = 6.925, p = 0.001, R: 13.2%). There was no relationship between OPG levels and CIMT or FMD.
Osteoprotegerin and CIMT levels were increased, and FMD measurements were decreased in patients with DM2. No association between CIMT, FMD, and OPG measurements was observed. The presence of DM and hypertension were associated with circulating OPG levels.
骨保护素（OPG）是一种抑制破骨细胞形成和活性的知名蛋白，它也可能是识别心血管风险高的患者的潜在标志物。本研究旨在比较糖尿病患者和非糖尿病患者的 OPG 水平、血流介导的舒张功能（FMD）和颈动脉内膜中层厚度（CIMT）的测量值，并探讨血清骨保护素水平与 2 型糖尿病（DM2）患者早期动脉粥样硬化标志物、内皮功能和颈动脉内膜中层厚度（CIMT）的关系。
本横断面研究纳入了 49 例 DM2 患者（F/M：26/23，49.3±10.0 岁）和 45 名健康志愿者（F/M：26/19，48.3±7.5 岁）。采用固相酶联免疫吸附试验（ELISA）法测定血清 OPG 水平。测定空腹血糖（FPG）和糖化血红蛋白（HbA1c）水平。采用 B 型超声测量 CIMT，采用多普勒超声评估肱动脉血流介导的舒张功能（FMD）。
DM2 患者的血清 OPG 水平（617.0±111.0 pg/mL）明显高于对照组（481.0±96.0 pg/mL，p<0.001）。糖尿病患者的 CIMT（0.65+0.13 mm）高于对照组（0.54±0.10 mm，p=0.009），而 DM2 组的 FMD 测量值较低（4.2%±3.1%mm 比 7.6%±4.1%mm，p=0.01）。单因素分析显示，OPG 与糖尿病（OR：6.999，p=0.001，R：15.1%）和高血压（OR=6.925，p=0.001，R：13.2%）有关。OPG 水平与 CIMT 或 FMD 之间无相关性。
2 型糖尿病患者的 OPG 和 CIMT 水平升高，FMD 测量值降低。CIMT、FMD 和 OPG 测量值之间无相关性。DM 和高血压的存在与循环 OPG 水平有关。
